Thalia Therapeutics plc has announced promising interim data from its phase I clinical trial in acute myeloid leukaemia (AML) in patients treated with miRisten (THAT-001).
The study is being conducted at City of Hope, one of the largest and most advanced cancer research and treatment organisations in the US. MiRisten is a first-in-class anti-miR-126 therapeutic designed to target leukaemia stem cells and their protective bone marrow microenvironment.
Nine patients with relapsed or refractory AML have been treated with miRisten to date, with a median age of 55 (27-79) and 55% were male. All participating patients had been heavily pretreated with a median of four prior lines of treatment targeting their disease.
Two dose levels have been completed, and the third dose level is enrolling the last patients on this monotherapy trial. Upon infusion, miRisten is immediately detectable in patient blood samples on pharmacokinetic assays, and levels of miR-126, the target of miRisten, are simultaneously reduced. A preliminary increase in SPRED1, a pharmacodynamic endpoint, was also observed, as would be expected when miR-126 is downregulated. Together, this suggests successful target engagement by miRisten.
Eight patients had no dose-limiting toxicity. Following treatment with miRisten, patients have had reductions in leukaemic blast cells and signs of improvements in neutrophil levels. In patients with AML, neutrophils (a key immune cell) decline and immature blast-like cells proliferate, which, together, are hallmarks of the disease. The increase of neutrophils in miRisten-treated patients suggests a positive impact towards normalising immune function in these patients.
One patient with prior neutropenia (loss of neutrophils) from relapsed AML had a transient complete response to treatment with an increase in neutrophils that has persisted for over a year. This patient experienced differentiation syndrome, had a concurrent infection, and was taken off treatment.
Standard leukaemia treatments primarily attack rapidly dividing cancer cells but routinely fail to eliminate leukaemic stem Cells (LSCs). These LSCs retreat into the bone marrow, entering a dormant state where they evade chemotherapy and inevitably drive disease relapse. The goal of miRisten therapy is to target LSCs by removing them to a dormant state and in turn altering their protective bone marrow microenvironment; this permits LSCs to be targeted by chemotherapeutic agents, including venetoclax. City of Hope research published in the peer-reviewed medical journal Blood showed pharmacologic inhibition of miR-126 with miRisten enhanced the antileukaemic activity of venetoclax in preclinical models of acute myeloid leukaemia.
David Solomon, CEO of Thalia, said: “These exciting data provide the first evidence in AML patients that our approach is achieving its intended biological effect and are an important safety and efficacy milestone for miRisten. This is particularly meaningful in relapsed or refractory AML, where patients have typically received multiple lines of prior therapy and have limited treatment options.
“Anti-miR therapeutics are a novel class of medicines, building on fundamental microRNA discoveries recognised by the 2024 Nobel Prize, and these data support the potential of this approach in AML. We look forward to completing the Phase I study and reporting topline data in H1 2027.”
Amanda Blackmon, principal investigator of the trial at City of Hope, said: “We are delighted to report promising clinical progress with a first-in-class targeted microRNA inhibitor representing a non-chemotherapeutic approach to treatment. Patients with relapsed or refractory AML face a poor prognosis with median survival consistently less than one year, and only around 10% are alive at three years. New therapies with a novel mechanism of action are urgently needed.
“City of Hope has successfully engineered miRisten to target a highly specific vulnerability in cancer biology: miR-126. It is encouraging to see evidence of drug delivery, target engagement and biological activity in relapsed and refractory patients, including improved neutrophil counts and reduced blast levels. We look forward to seeing the data in the remaining patients in the trial.”


